Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Fish oil showdown: which type fights diabetes best?

NCT ID NCT07575438

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether two types of fish oil, EPA and DHA, can improve metabolic health in people at high risk for type 2 diabetes. Over 12 weeks, 84 participants will take daily capsules of EPA, DHA, or a placebo (corn oil) and undergo specialized tests to measure insulin function, cholesterol quality, and fat tissue health. The goal is to see if one fish oil works better than the other at preventing diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Males and post-menopausal females: * With a body mass index (BMI \>25-40 kg/m2) * Having confirmed menopausal status (FSH ≥ 30 U/l) * Non-smokers (tobacco) or have quitted for over a year * Low-moderate alcohol consumption: \<7 alcoholic servings/ week * Plasma apoB ≥1.05 g/L Exclusion Criteria: * Elevated risk of cardiovascular disease (≥ 20% of calculated Framingham Risk Score) * Prior history of cardiovascular events (e.g. stroke, transient ischemic attack, myocardial infarction, angina, heart failure, arrhythmias, flutter, atrial …) * Systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg * Diabetes or HbA1c ≥ 6.5% * Reactive hypoglycaemia * Prior history of cancer within the last 3 years or if lymph nodes were removed * Thyroid disease - untreated or unstable Synthroid dose * Severe renal dysfunction - eGFR \< 30 mL/min/1.73 m² * Hepatic dysfunction - AST/ALT \> 3 times normal limit * Anemia - Hb \< 120 g/L in females and \< 130 in males * Bleeding disorders * Blood coagulation problems (i.e. bleeding predisposition) * Malabsorptive disease or surgeries (e.g. bariatric surgeries) * Autoimmune and chronic inflammatory disease (i.e. celiac, inflammatory bowel, Graves, multiple sclerosis, psoriasis, rheumatoid arthritis, and lupus). * Chronic diarrhea * Cholecystectomy (e.g. removal of gall bladder) * Sleep apnea * Seizures * Known history of difficulties accessing a vein * Known history of vagal shock or loss of consciousness during blood withdrawal * Concomitant medications (systemic corticosteroids; hypertension medication; anti-psychotic medications - psycho-active medication that promote weight gain; anticoagulant or anti-aggregates treatment (e.g. aspirin, NSAIDs, warfarin, coumadin..); systemic adrenergic agonists; weight-loss medication (e.g. GLP-1 agonists); lipid lowering medication (e.g. statins, anti-PCSK9); ) * Allergy to seafood/fish or corn oil * Allergy to bovine gelatine or glycerine (softgel components) * Allergy to Xylocaine (anesthesia used during fat tissue biopsy) * Anticipated surgery or blood transfusion * Known substance abuse * Very high physical activity (\> 5 hours of aerobic exercise per week) * Already taking more than 1 gm of EPA and/or DHA supplementation per day * Lack of compliance to the study requirements (i.e. not being fasting) * Cancellation of the same scheduled testing visit more than once * Lack of time to participate in the full length of the study (18-22 weeks) * Other conditions deemed inappropriate by the study physician (e.g. difficulties in understanding/communicating in French or English)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Institut de recherches cliniques de Montréal (IRCM)

    Montreal, Quebec, H2W 1R7, Canada

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.